SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 287 filers reported holding SAGE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $562,000 | -32.6% | 4,008 | -12.0% | 0.00% | -33.3% |
| Q2 2019 | $834,000 | +20.9% | 4,557 | +5.0% | 0.01% | 0.0% |
| Q1 2019 | $690,000 | +67.1% | 4,338 | +0.6% | 0.01% | +50.0% |
| Q4 2018 | $413,000 | -49.6% | 4,311 | -25.8% | 0.00% | -42.9% |
| Q3 2018 | $820,000 | -6.4% | 5,807 | +3.8% | 0.01% | -12.5% |
| Q2 2018 | $876,000 | +20.3% | 5,597 | +23.9% | 0.01% | +14.3% |
| Q1 2018 | $728,000 | +56.9% | 4,517 | +60.3% | 0.01% | +40.0% |
| Q4 2017 | $464,000 | +81.2% | 2,818 | -21.7% | 0.01% | +66.7% |
| Q1 2017 | $256,000 | – | 3,599 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |